Skip to content
AnalystLens

Medpace Holdings 8-K Report, Financial Results (Jul 22, 2024)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed July 22, 2024
Period End
July 22, 2024
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 8-K filed July 22, 2024. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (Nasdaq: MEDP) furnished a press release under Item 2.02 reporting its financial results for the three and six months ended June 30, 2024.

Revenue for the second quarter of 2024 was $528.1 milliona, up 14.6% from $460.9 million a year earlier, with a backlog conversion rate of 18.2%. Net new business awards were $551.0 million, a 4.1% decrease from $574.8 million, producing a net book-to-bill ratio of 1.04x. GAAP net income rose to $88.4 million, or $2.75 per diluted share, from $61.1 million, or $1.93 per diluted share, and EBITDA increased 34.2% to $112.3 million, a 21.3% margin.

For the first half of 2024, revenue was $1,039.1 millionb, up 16.1%, and GAAP net income was $190.9 million, or $5.96 per diluted share. Backlog as of June 30, 2024 increased 13.7% to $2,924.9 million. Cash and cash equivalents were $510.9 million at quarter end, and the company reported no share repurchases in the second quarter, with $308.8 million remaining under its authorized repurchase program.

For full-year 2024, the company forecasts revenue of $2.125 billion to $2.175 billionc, GAAP net income of $361.0 million to $383.0 million, EBITDA of $430.0 million to $460.0 million, and diluted EPS of $11.24 to $11.93. The guidance assumes a tax rate of 15.0% to 16.0%, interest income of $24.0 million, and 32.1 million diluted shares, and excludes any repurchases after June 30, 2024.

A conference call is scheduled for 9:00 a.m. ET on July 23, 2024.

Key Highlights

  1. Q2 2024 revenue of $528.1 million, up 14.6% year over year, with a backlog conversion rate of 18.2%.
  2. Q2 2024 net new business awards of $551.0 million, down 4.1% from $574.8 million, for a net book-to-bill ratio of 1.04x.
  3. Q2 2024 GAAP net income of $88.4 million ($2.75 per diluted share) versus $61.1 million ($1.93) a year earlier; net income margin of 16.7% versus 13.3%.
  4. Q2 2024 EBITDA of $112.3 million, up 34.2%, with a 21.3% EBITDA margin.
  5. Backlog at June 30, 2024 of $2,924.9 million, up 13.7% from $2,571.9 million a year earlier.
  6. Full-year 2024 guidance: revenue of $2.125 billion to $2.175 billion, GAAP net income of $361.0 million to $383.0 million, and diluted EPS of $11.24 to $11.93.
  7. Cash and cash equivalents of $510.9 million at June 30, 2024; no share repurchases in Q2 2024, with $308.8 million remaining under the authorized program.

Frequently Asked Questions

  1. How did Medpace perform in the second quarter of 2024?

    Revenue rose 14.6% to $528.1 million, GAAP net income increased to $88.4 million ($2.75 per diluted share) from $61.1 million ($1.93), and EBITDA grew 34.2% to $112.3 million. Net income margin improved to 16.7% from 13.3%.

  2. Did new business awards keep pace with revenue?

    Not quite. Net new business awards were $551.0 million, down 4.1% from $574.8 million in the prior-year quarter, which produced a net book-to-bill ratio of 1.04x. Backlog nonetheless grew 13.7% to $2,924.9 million as of June 30, 2024.

  3. What is the company's full-year 2024 outlook?

    Medpace forecasts 2024 revenue of $2.125 billion to $2.175 billion, GAAP net income of $361.0 million to $383.0 million, EBITDA of $430.0 million to $460.0 million, and GAAP diluted EPS of $11.24 to $11.93. The guidance assumes a 15.0% to 16.0% tax rate, $24.0 million of interest income, and 32.1 million diluted shares, and excludes share repurchases after June 30, 2024.

  4. What is the company's capital position and capital return activity?

    Cash and cash equivalents were $510.9 million at June 30, 2024, and operating cash flow in Q2 2024 was $116.4 million. The company made no share repurchases in the second quarter and had $308.8 million remaining under its authorized repurchase program.

  5. When and how can investors access the second-quarter results discussion?

    Medpace will host a conference call at 9:00 a.m. ET on Tuesday, July 23, 2024, with a webcast and replay available in the Investors section of its website at medpace.com, along with a supplemental slide presentation.